A Phase I Dose-Escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.
Sarah HalfordGareth J VealStephen R WedgeGeoffrey S PayneChris M BaconPhilip SloanIlaria DragoniKathrin HeinzmannSarah PotterBecky M SalisburyMaxime Chénard-PoirierAlastair GreystokeElizabeth C HowellWilliam A InnesKaren MorrisChris PlummerMihaela RataGeorge PetridesHector C KeunUdai BanerjiRuth PlummerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
AZD3965 is tolerated at doses that produce target engagement. DLTs were on-target and primarily dose-dependent, asymptomatic, reversible ocular changes. An RP2D of 10 mg BD was established for use in dose-expansion in cancers that generally express high MCT1/low MCT4 (not yet published).